News

Support from the National Institute of Diabetes and Digestive and Kidney Diseases will help reveal how a newly discovered rare cell impacts the autoimmune disease.

The California Institute for Regenerative Medicine (CIRM) grant supports the development of a new technology designed to restore normal gene function in select neurodevelopmental disorders.

An NIH-backed effort aims to decode how the nervous system monitors internal organs.

New findings reveal how specialized cells shield the pancreas from autoimmune attack, providing new therapeutic strategies for type 1 diabetes.

The novel computer method to encode synthetic protein sequences within cell lipid environments offers insights into how membrane proteins fold and function, critical to understanding disease.

Shimon Sakaguchi is honored for his revolutionary discovery of regulatory T cells—revealing how “immune tolerance” impacts autoimmune diseases, cancer and more.

Associate Professor Xin Jin selected for up to two five-year terms, receiving up to $8.6 million over 10 years to support neuroscience and genomic research.

Study by Scripps Research scientists shows how the brain learns to seek alcohol for relief, not just pleasurable effects, in an animal model.

Scripps Research study shows how smartwatch and fitness tracker data align with hormonal changes, offering the potential for early detection of complications.

Scripps Research breakthrough reduces antibody discovery time from weeks to hours, potentially revolutionizing pandemic response and therapeutic development.

Findings from Scripps Research reveal promising drug targets with potential to block coronaviruses at multiple stages of infection—even across different strains.

Study led by Scripps Research, Texas A&M and additional institutions highlights that the world’s deadliest infectious disease needs novel, effective antibiotics.

A new platform developed at Scripps Research enables fast, scalable protein evolution—opening the door to new therapies and diagnostics, and to predicting resistance mutations across many disease areas.

Phase 3 trial results from Scripps Research and collaborators helped support FDA approval of ENCELTO, the first cell-based therapy for a neurodegenerative retinal condition called MacTel.

Scripps Research scientists reveal how wearable sensors and artificial intelligence could transform the way we detect and manage pre-diabetes.

The grant from the National Center for Advancing Translational Sciences (NCATS) supports the ongoing development of the Biomedical Data Translator—an open-source resource to accelerate human health insights.

Origin-of-life scientists from Scripps Research reveal how the sugar ribose may have been selected as one of life’s building blocks.

First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps — early warning signs of colorectal cancer — before they become cancerous.Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions.

By analyzing just a drop of blood, this microchip gives researchers quicker-than-ever insight into how a person’s antibodies are interacting with a virus or other pathogen.

Scripps Research scientists’ new approach combines two immune-activating molecules known as adjuvants.

CLBR001 + ABBV-461 is a novel, investigational, two-part, switchable chimeric antigen T cell (sCAR-T) immunotherapy designed to treat solid tumors.

Cell-based therapy with roots at Scripps Research offers new hope for patients with macular telangiectasia type 2.

Scripps Research’s insights into sex-based differences in brain chemistry could guide personalized treatment strategies for alcohol use disorder.

More than 70% of the drugs identified by artificial intelligence extended the lifespan of C. elegans worms.